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Abstract
Purpose Both carbon monoxide (CO) and nitric oxide (NO)
are two gaseous molecules performing relevant functions in
mammals. In order to better understand their actions in the
cardiovascular system, we have investigated the effects of
CORM-3, (tricarbonylchloro(glycinato)ruthenium(II), a wa-
ter soluble CO-releasing molecule and SNAP (S-nitroso-N-
acetyl-DL-penicillamine, a well known NO-releasing mole-
cule) on aortas of normotensive Wistar Kyoto (WKY) and
spontaneously hypertensive rats (SHR).
Methods The isometric contraction of angiotensin II (AT-II)
and endothelin-1 (ET-1) was evaluated in endothelium-
denuded aortic strips.
Results In control conditions, AT-II induced a similar
concentration-dependent contraction in both WKY and
SHR, while ET-1 was more effective in SHR aortic strips.
CORM-3 or SNAP (10−7–3×10−4 M) reduced the contrac-
tion induced by AT-II or ET-1 in a concentration-dependent
way. Whereas the median inhibitory concentration of SNAP
was significantly lower in WKY than in SHR, CORM-3 had
a similar effect in both strains. The scaffold compound
iCORM-3 was ineffective. Pretreatment with an inhibitor
of soluble guanylyl cyclase (ODQ, 3×10−6 M) marginally
reduced CORM-3 relaxation in both strains, whereas it
reduced relaxation induced by SNAP in WKY and, to a
lesser extent, in SHR. The benzylindazole derivative YC-1
(10−6 M), a sensitizer of soluble guanylate cyclase to the
action of NO, significantly increased the relaxant effect of
SNAP in AT-II precontracted aortic strips. The blocker of
calcium-activated potassium channels, charybdotoxin
(10−8 M), reduced the relaxation induced by CORM-3 in
both strains.
Conclusions Different mechanisms seem to be implicated in
CO- and NO-mediated vascular relaxation. Since the relaxant
properties of CO are conserved in SHR aortas, CORM-3
could be a new potential agent for the treatment of hyperten-
sion, when NO donors show sub-optimal or absent responses.
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Introduction
Mammalian cells constantly generate carbon monoxide
(CO) gas via the endogenous degradation of heme by a
family of constitutive (HO-2 and HO-3) and inducible
(HO-1) heme oxygenase (HO) enzymes [1].
CO is a versatile signalling molecule with essential reg-
ulatory roles in a variety of physiological and pathological
processes [2–4] In the cardiovascular system, CO exerts an
important relaxant effect [5] which is shared with the
endothelium-derived relaxing factor nitric oxide (NO) gen-
erated by the constitutive isoform of endothelial NO syn-
thase (eNOS) [6]. CO, like NO, activates soluble guanylate
cyclase [7], although its effect is less potent than that exerted
by NO [8, 9]. Although this mechanism contributes to the
relaxant effect of CO, it has been demonstrated that CO can
directly activate big-conductance calcium-activated potassi-
um channels (BK channels) [10], resulting in membrane
hyperpolarization and relaxation in precontracted arteries.
These findings have prompted many researchers to con-
sider CO as a potent therapeutic tool in the treatment of
vascular dysfunction, leading to the synthesis and charac-
terization of CO-releasing compounds, among which are
transition metal carbonyl compounds capable of carrying
and delivering CO into biological systems and possessing
vasodilatory properties [11].
Systemic hypertension impairs vascular tone, increases
arterial blood pressure and is a major risk for patients with
cardiovascular diseases. While the physiological and phar-
macological role of NO in hypertension is well established,
that of CO in this pathological condition is less clear.
Thus, the purpose of this study was to assess the effect of
the water soluble carbon monoxide-releasing molecule
CORM-3 [12, 13] on aortas of control normotensive Wistar
Kyoto (WKY) and spontaneously hypertensive (SHR) rats
in comparison with S-nitroso-N-acetyl-DL-penicellamine
(SNAP), an NO donor. Angiotensin-II (AT-II) and
endothelin-1 (ET-1) are very potent contractile agonists of
the vasculature system, both of them implicated in human
hypertension. Their contractile action on vascular smooth
muscle cells is mediated via an increase in cytosolic Ca2+.
However, mechanisms of this process are different between
the two agents.
Endothelin-1 increases intracellular Ca2+ by stimulating
influx through Ca2+ channels [14] and is known to produce
a much more sustained contraction by the vascular smooth
muscle cells, whereas angiotensin II elicits a biphasic re-
sponse that is generated primarily by mobilization of Ca2+
from intracellular stores followed by Ca2+ entry [15]. Given
the different mechanisms for smooth muscle contraction of
these agonists, we decided to investigate the relaxant
effect of NO and CO on preparations precontracted with
AT-II or ET-1.
Methods
Synthesis of CORM-3 and other chemicals
CORM-3 was synthesized as described previously [12, 13]
and was prepared as a 10 mM stock by dissolving the
compound in pure distilled water. It was kept at −20 °C
and defrosted before each experiment. Final concentrations
of CORM-3 were prepared immediately before their use.
Inactive CORM-3 (iCORM-3) was obtained by leaving
CORM-3 in phosphate buffer saline (PBS), pH 7.4 at room
temperature overnight to permit the release of all available
CO from the molecule [12]. This treatment produces an
inactive carrier molecule that no longer releases CO
(iCORM-3), which was used as a negative control [13].
Angiotensin II (AT-II), endothelin-1 (ET-1) and char-
ybdotoxin (CHTX) were purchased from Sigma Chemical
Co. (Milan, Italy), S-nitroso-Nacetyl-DL-penicillamine
(SNAP) from Tocris Cookson Ltd (Bristol, UK), 1H-
(1,2,4)-oxadiazolo(4,2-a)quinoxalin-1-one (ODQ) from
Calbiochem (Milan, Italy) and 3-(5′-hidroxymethyl-2′-
furyl)-1-benzylindosole (YC-1) from Alexis Corporation
(Nottingham, UK). All other chemicals used in the study
were from Sigma Chemical Co. (Milan, Italy), unless
otherwise specified.
Detection of carbon monoxide (CO) release from CORM-3
and iCORM-3
The amount of CO liberated by CORM-3 and iCORM-3
was measured with an ultra-trace gas detection system
(RGA3, Reduction Gas Analyzer, SAES Getters, Milan,
Italy) dedicated to CO detection as already described [16]
with few modifications. Briefly, 2 ml of PBS solution
(pH 7.4) containing different concentrations of CORM-3
and iCORM-3 (10 nM–1 mM) were incubated at 37 °C in
sample vials. The gas developing in 2 min was collected in
the headspace of the vial and transferred to the reduction gas
analyzer via a two-needle assembly attached to the injection
valve. This valve was controlled by a timer. The head space
gas components were separated chromatographically within
an isothermal mandrel-heating column oven at a tempera-
ture of 100 °C with CO-free air carrier gas (N2 70 cc/min).
Species eluting from the chromatographic column passed
immediately into the detector. CO was quantified in the
detector by means of A254 of Hg generated from the reaction
of CO with HgO at 225 °C. A 10-mV recorder charted the
detector response in terms of peak height at a paper speed of
10 mm/min. Peak heights and areas were used to correlate
detector response between standards and unknowns. A
CO standard curve was prepared immediately prior to
sample analysis. Standard gas was obtained from a com-
mercial source (Rivoira, Milan). The method allowed the
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precise determination of the CO amount developed by
the studied molecules.
Animals
All animal manipulations were carried out according to the
European Community guidelines for animal care (DL 116/
92, application of the European Communities Council Di-
rective 86/609/EEC). The ethical policy of the University of
Florence conforms with the Guide for the Care and Use of
Laboratory Animals of the US National Institutes of Health
(NIH Publication No. 85-23, revised 1996; University of
Florence assurance number: A5278-01). Formal approval to
conduct the experiments described was obtained from the
animal subject review board of the University of Florence.
For all experiments described herein, 12–14-week-old male
normotensive WKY (310.5±6.95 g) and age-matched SHR
(311.7±9.26 g) were used (Charles River, Italy). Four rats
were housed per cage (size 26×41 cm); animals were fed
standard laboratory diet and tap water ad libitum, and kept at
23±1 °C with a 12 h light/dark cycle, light at 7 a.m. Animals
were killed by cervical dislocation.
Functional studies on rat thoracic aortas
Thoracic aortas were isolated from WKY and SHR and,
after removing the endothelium by rubbing the cell layer
with a cotton swab, were mounted in an organ bath of 2 ml
volume [17].
The strips were perfused with pre-warmed (37 °C) Krebs-
Henseleit solution, (pH 7.4) of the following composition (mM):
110 NaCl, 25 NaHCO3, 4.8 KCl, 1.2 KH2PO4, 1.2 MgSO4, 11
(+) glucose, 2.5 CaCl2, and gassed with 5 % CO2 in O2. The
resting tension applied to the aorta preparation was 0.7 g.
After 60 min of stabilization, the absence of endothelium
was tested as previously reported [18], and cumulative
concentration-response curves of AT-II or ET-1 were per-
formed in different aortic preparations. Then, strips were
extensively washed, re-stabilized and precontracted using
the maximal contracting dose of AT-II or ET-1 (100 % of
contractile response). Cumulative concentration-response
curves of either CORM-3 or SNAP were performed in
control conditions or after the preincubation (30 min, 37 °C)
with 3×10−6 M ODQ or 10−8 M CHTX.
The effects of CORM-3 and SNAP on vascular relaxation
were also assessed in the presence of the soluble guanylate
cyclase stimulator, YC-1 (10−6 M, which was added 30 min
before AT-II or ET-1).
Determination of cyclic GMP levels
Wiped, frozen arteries from WKYand SHR obtained from the
different experiments were homogenized in 6 % trichloroacetic
acid (TCA) and the samples were centrifuged at 2,000 × g for
15 min. at 4 °C. The precipitate was discarded and TCA was
removed from the supernatant by extraction with 5 ml of ether
(three times). Residual ether was removed by heating the
samples to 70 °C for 5 min.
Cyclic GMP (cGMP) concentration was determined us-
ing a competitive enzyme immunoassay kit (Cayman Chem-
icals, Ann Arbor, MI, U.S.A.). The cGMP content of each
sample was divided by tissue wet weight and expressed as
pmol.mg−1 tissue.
Data handling and statistical analysis
Data are reported as means ± s.e.m. of at least six different
experiments per group. Sigmoidal concentration-response
curves were plotted with OriginPro® (version 8.1) program
and compared with one-way ANOVA followed by Bonfer-
roni’s t test. The EC50 and IC50 were calculated using the
OriginPro® (version 8.1) program in each single curve and
compared with one-way ANOVA followed by Bonferroni’s
t test. A P≤0.05 was considered significant.
Results
Detection of CO release from CORM-3 and iCORM-3
The release of CO from CORM-3 solution at different con-
centrations (pH07.4, 37 °C) is reported in Fig. 1. As shown,
the CORM-3 solution spontaneously released CO in a
concentration-dependent way in the range from 10 nM to
10 mM.
Predictably, iCORM-3 did not release CO at all the tested
concentrations, as reported in Fig. 1.
Effect of ET-1 and AT-II on isolated aortas
We tested the contractile effect of AT-II and ET-1 on endo-
thelium denuded aortas isolated from WKY and SHR. The
Fig. 1 Release of carbon monoxide (p.p.m.) from CORM-3 and
iCORM-3 solutions at different concentrations, pH 7.4, 37 °C. The
values are means ± s.e.m. of six determinations performed in duplicate
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cumulative concentration-response curves of AT-II were
similar in WKY and SHR preparations in the full range
(10−10–10−6 M, Fig. 2a), the maximal contractile effect
being obtained at 10−7 M AT-II. ET-1 was more active than
AT-II in evoking contraction in both strains, its effect being
significantly higher (p<0.001) in aortas isolated from SHR
than WKY, even if ET-1 full contractility was obtained at
10−8 M in both strains (Fig. 2b).
Vasodilatatory effects of CORM-3 and SNAP in aortic rings
isolated from WKY and SHR rats
It has been shown that CORM-3 promotes rapid and signif-
icant relaxation in rat aortic rings precontracted with phen-
ylephrine, its effect being mediated by CO [15]. Therefore,
we tested the effect of CORM-3 on aortic strips isolated
from WKY and SHR and precontracted with 10−7 M AT-II
or 10−8 M ET-1. CORM-3 relaxed precontracted aortic
preparations from both strains, its maximal effect occurring
at 10−4 M when AT-II was used as contractile agonist
(Fig. 3a) and 3×10−4 M (the maximal concentration usable
in our protocol) in ET-1 contraction (Fig. 3b). The CORM-3
concentration-dependent curves were similar at all concen-
trations tested, independently of the rat strain and contractile
agonist used. This comparable effectiveness of CORM-3 in
WKY and SHR was also reflected by the median inhibitory
concentrations (IC50s) on 10−7 M AT-II, and in 10−8 M ET-
1 precontracted preparations (Table 1). In parallel experi-
ments, AT-II or ET-1 precontracted aortic strips were also
treated with 300 μM iCORM, the inactive compound which
was totally ineffective (data not shown).
Compared to the NO releaser SNAP, CORM-3 showed
reduced activity in relaxing WKY aortic preparations, but a
similar effectiveness in SHR at all concentrations tested
(Fig. 3, panel A and B). To note that SNAP was significantly
less potent in SHR than WKY preparations: indeed, the
IC50s were about 9 and 6 fold higher in SHR than in
WKY in AT-II and ET-1 precontracted preparations respec-
tively (Table 1). On the other hand, CORM-3 showed a
similar potency in SHR and WKY preparations and, in
SHR aortic strips, its IC50s tending to be lower than those
calculated for SNAP in the same strain.
CO-mediated vasorelaxation by CORM-3: possible mecha-
nisms of action
It is well established that CO, endogenously generated from
HO-1, exogenously applied as CO gas or delivered by
CORMs, behaves by activating several intracellular targets
and these actions are shared with NO. For example, activa-
tion of soluble guanylyl cyclase [7] and potassium channels
[10] has been demonstrated for both CO and NO. Therefore,
we performed experiments in order to ascertain the possible
multiple mechanisms in the relaxation induced by CO and
NO of aortic strips precontracted with AT-II and ET-1.
Fig. 2 Concentration-response curves of angiotensin-II (AT-II, panel
a) and endothelin-1 (ET-1, panel b) on endothelium–denuded rat aortic
strips isolated from WKY (□) and SHR (•). The values are means ±
s.e.m. of 6 different preparations. *P<0.001 vs WKYpreparations, one
way ANOVA followed by Bonferroni’s test
Fig. 3 Concentration-response
curves of CORM-3 (bold sym-
bols •) and SNAP (open sym-
bols □) on endothelium-
denuded rat aortic strips isolat-
ed from WKY (solid line) and
SHR (dot line) pre-contracted
with 10−7 M AT-II (panel a) and
10−8 M ET-1 (panel b). The
values are means ± s.e.m. of at
least 6 different preparations.
*P<0.001 one way ANOVA
followed by Bonferroni’s test
SNAP in WKY preparations vs
all other treatments in SHR
preparations
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We found that the soluble guanylate cyclase inhibitor ODQ
(3×10−6 M) reduced the vasodilatation determined by the
highest doses (10−4–3·10−4 M) of CORM-3 in preparations
isolated from both strains and precontracted either with
10−7 M AT-II (Fig. 4, panels A and B) or 10−8 M ET-1
(Fig. 5, panels A and B). On the other hand, ODQ was more
effective in inhibiting SNAP than CORM-3 relaxation (Fig. 4,
panels C and D, AT-II contraction; Fig. 5, panels C and D, ET-
1 contraction). Particularly inWKYaortic strips precontracted
with AT-II or ET-1, ODQ shifted the concentration-dependent
curve to the right in the full range of SNAP concentrations. In
SHR, ODQ reduced SNAP efficacy at high SNAP concen-
trations only (10−5 M–3×10−4 M).
To further investigate the involvement of soluble gua-
nylyl cyclase in mediating the effect of CO and NO, we
evaluated the levels of cGMP in aortic preparations isolated
from WKY and SHR and preincubated with 3×10−4 M
CORM-3 or 10−5 M SNAP (Table 2). The level of cGMP
in control conditions was significantly higher in WKY than
in SHR preparations. Nevertheless, the treatment with 3×
10−4 M CORM-3 increased cGMP contents to a similar
value in WKY and SHR. Also 10−5 M SNAP significantly
increased cGMP up to 6 times in WKYand up to 5.86 times
in SHR preparations as compared to their respective control
values (Table 2).
The benzylindazole derivative, YC-1 is known to sensi-
tize soluble guanylate cyclase to the action of NO [19].
When aorta preparations were pre-incubated with 10−6 M
YC-1 and precontracted with AT-II, the relaxing effect of
SNAP was significantly increased at all concentrations test-
ed in preparations isolated from WKY and, to a lesser
extent, in SHR (Fig. 4, panels A and B); on the contrary
the sensitizing action of YC-1 on the relaxing effect of
CORM-3 was practically absent in preparations isolated
from both strains (Fig. 4).
The BK channel blocker CHTX (10−8 M) reduced
CORM-3 relaxation in WKYand SHR preparations precon-
tracted with AT-II or ET-1 and shared a similar or higher
effectiveness than ODQ in reducing CORM-3 relaxation
(Figs. 4 and 5, panels A and B). However, CHTX was less
effective than ODQ in reducing SNAP relaxation of WKY
precontracted with AT-II (Fig. 4, panel C), but it was simi-
larly effective when the contraction was induced by ET-1
(Fig. 5, panel C). Moreover, SNAP relaxation was reduced
by CHTX more efficiently in WKY than in SHR aortic
strips precontracted with both agonists (Figs. 4 and 5, panels
C and D).
Table 1 Median inhibitory concentrations (IC50%) of SNAP and
CORM-3 in aorta preparations isolated from WKY and SHR rats pre-
contracted with AT-II or ET-1
CORM-3 SNAP
10−7 M AT-II
WKY 2.6±0.48 μM 0.4±0.05 μM
SHR 1.9±0,73 μM 3.0±0.31 μM *
10−8 M ET-1
WKY 13.8±1.26 μM 3.5±0.45 μM
SHR 15.6±1.75 μM 21.3±2.88 μM *
The values are the means ± s.e.m. of 6 different preparations. IC50%s
were calculated for each different preparation from its concentration-
response curve. *P<0.001 vs WKY SNAP, one way ANOVA followed
by Bonferroni’s test
Fig. 4 Concentration-response
curve of CORM-3 (WKY panel
a, SHR panel b) or SNAP
(WKYpanel c, SHR panel d) in
control condition (■, solid line),
in the presence of 3×10−6 M
ODQ (•, dot line), 10−8 M
CHTX (▲, dash line), 10−6 M
YC-1 (❆, short dash line) on
endothelium-denuded rat aortic
strips isolated from WKY
(panels a and c) and SHR
(panels b and d) and precon-
tracted with 10−7 M AT-II.
Aortic preparations were pre-
treated with ODQ or CHTX for
30 min before contraction with
10−7 M AT-II. Values are means
± s.e.m. of 6 preparations.
*P<0.05 one way ANOVA
followed by Bonferroni’s test,
vs control
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Discussion
The present study shows that tricarbonylchloro(glycinato)
ruthenium(II), CORM-3 promotes significant relaxation in
aortas isolated from WKY and SHR and precontracted with
AT-II or ET-1.
CORM-3 as already demonstrated is a highly water sol-
uble, rapid CO releaser molecule [12, 13]. As measured by
reduction gas analyzer, CORM-3 can release CO in a
concentration-dependent fashion. Although the CO quantity
detected is lower than the CORM-3 concentration used, this
measurement allows to perform concentration-response
curves with CORM-3 on biological preparations.
Like NO, CO is a relaxing factor which induces relaxa-
tion of vascular muscle cells by several mechanisms includ-
ing the stimulation of soluble guanylate cyclase/cGMP/
cyclic dependent protein kinase I pathway and various types
of potassium channels [3, 8]. All these mechanisms can con-
tribute in a different way to the final relaxation according to
the different vascular districts, contractile agents used and
patho-physiological experimental models.
Vascular tissue isolated from SHR is a widely used model
of experimental hypertension, even if it represents a genetic
form of hypertension and therefore it reflects only a subtype
of human hypertension. On the other hand, several naturally-
occurring cardiac and renal derangements in SHR, especially
older ones, are very similar to those observed in human
essential hypertension [20]. Therefore, studies in this hyper-
tensive animal model can suggest useful information on the
action of pharmacological agents. Moreover, early studies on
7-week old SHR demonstrate that a 4 day treatment with
stannous chloride (SnCl2) can increase HO-1 activity in the
kidney and decreases blood pressure [21]. However, the
blood pressure is not modified by a similar treatment in 20-
week old animals. These results suggests that CO may lower
blood pressure.
In our study we tested the relaxing effect of CORM-3 and
SNAP in endothelium denuded precontracted aortic prepa-
rations, isolated from SHR and WKY rats. It is well known
that endothelium is the major source of NO [6]. Therefore,
in its absence it is unlikely that endogenous produced NO
can influence the effect of both exogenous vasodilators.
CORM-3 and SNAP relax aortic strips precontracted
with both AT-II and ET-1 in a concentration-dependent
way although the vasodilator responses induced by CORM-
3 and SNAP are different in the four studied groups. In
particular, both relaxing agents are less effective when aortas
are contracted with ET-1 that, according to literature data
[22], produces a much stronger contraction than AT-II as a
result to its different Ca2+ mobilizing mechanisms [14, 15,
22]. Particularly in SHR, its maximal effect is significantly
Fig. 5 Concentration-response
curve of CORM-3 (WKY panel
a, SHR panel b) or SNAP
(WKYpanel c, SHR panel d) in
control condition (■, solid line),
in the presence of 3×10−6 M
ODQ (•, dot line), 10−8 M
CHTX (▲, dash line) on
endothelium-denuded rat aortic
strips isolated from WKY
(panels a and c) and SHR
(panels b and d) and precon-
tracted with 10−8 M ET-1. Aor-
tic preparations were pre-
treated with ODQ or CHTX for
30 min before contraction with
10−8 M ET-1. Values are means
± s.e.m. of 6 preparations. *P<
0.05 one way ANOVA fol-
lowed by Bonferroni’s test, vs
control
Table 2 Effect of CORM-3 and SNAP on cGMP levels of isolated
WKY and SHR aortic strips
Cyclic guanosyl monophosphate (cGMP) levels (pmol/mg tissue w.w.)
WKY SHR
Control 1.2±0.11 0.7±0.12*
3×10−4 M CORM-3 5.4±0.72 5.5±0.95
10−5 M SNAP 7.2±0.82 4.1±0.51**
*P<0.05, one way ANOVA followed by Bonferroni’s test, SHR vs
WKY control, **P<0.01 one way ANOVA followed by Bonferroni’s
test, SHR vs WKY SNAP
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higher than in WKY aortas. Therefore, the reduced effective-
ness of both CORM-3 and SNAP in ET-1 precontracted
preparations could be related to the stronger contraction
induced by ET-1.
In preparations isolated from WKY rats, CORM-3 is less
potent than SNAP in relaxing AT-II or ET-1 -precontracted
preparations, but CORM-3 shows a similar effectiveness in
SHR aortic strips. Whereas the SNAP-induced relaxation is
significantly decreased in preparations from SHR as com-
pared to WKYones, the vasodilator response to CORM-3 is
of the same extent in both strains as demonstrated by their
IC50s.
The SNAP-induced relaxation is strongly decreased by
ODQ and this effect is particularly evident in WKY where it
decreases relaxation at all SNAP concentrations used. On
the other hand, CORM-3 relaxation is only affected by ODQ
at high CORM-3 concentrations (10−4–3×10−4 M), suggest-
ing that different pathways may predominate in SNAP and
CORM-3 relaxation, at least at low CORM-3 concentra-
tions. It seems that in our experimental conditions, the
cGMP pathway is the prominent mechanism involved in
the SNAP effect, but it plays a less important role in
CORM-3 relaxation. The experiments performed by prein-
cubating the aorta preparations with YC-1, a soluble guany-
late cyclase sensitizing agent confirmed this hypothesis. It
should also be remembered that CO activation of soluble
guanylate cyclase differs by several orders of magnitude
from that elicited by NO [8, 9]. In agreement with these
data, our results show a significant increase in cGMP con-
tent after 3×10−4 M CORM-3 or 10−5 M SNAP treatment of
isolated aortas, while NO, at a low concentration, was more
effective than CO in increasing cGMP in WKY rats. This
different sensitivity of soluble guanylate cyclase activation
by NO and CO could explain why ODQ prevents relaxation
only at a high CORM-3 concentration. In preparations iso-
lated from SHR, the increase in cGMP induced by SNAP is
significantly lower than in those isolated from WKY rats as
well as the relaxation induced by SNAP of precontracted
aortas. This result is not unexpected, since the cGMP path-
way is impaired in SHR. Soluble guanylate cyclase and
cGMP-dependent protein kinase expression are decreased
in SHR aortas [23] and functionally, SNAP and the
membrane-permeable dibutirryl cyclic GMP do not regulate
intracellular calcium concentrations in aortic smooth muscle
cells isolated from SHR [24].
CHTX is at least similar or more effective than ODQ in
reducing CORM-3 relaxation in both SHR and WKY aortic
strips, but less active in inhibiting SNAP relaxation, sug-
gesting that potassium channels are chiefly involved in CO
relaxation, but represent a secondary pathway in NO relaxa-
tion. CO and NO can activate potassium channels with dif-
ferent modalities [25]. In particular, the stimulatory effects of
CO depends on specific interaction with the α-subunit of the
calcium activated potassium channel (KCa,α), while NO
activation relies on β-subunit (KCa,β), although it can also
bind the α-subunit [25]. Pioneer studies on aortas and aortic
isolated smooth muscle cells of SHR [26, 27] describe an up-
regulation of BK that can represent a compensatory mecha-
nism in the hypertension setting. Therefore, CO that targets
potassium channels in cardiovascular pathologies, such as
hypertension, can provide alternative vasodilator therapies
to the traditional agents acting via direct or indirect NO
production. Moreover, a recent report suggests the involve-
ment of ATP-dependent (KATP) potassium channels as part of
the dilatatory mechanisms exerted by CORM-3 [13]. How-
ever, other authors report the central role of the KCa,α in CO
effect [25, 28, 29].
In conclusion, an agent which can relax vasculature in-
dependently of cGMP-dependent protein kinase could rep-
resent a suitable pharmacological approach in clinical
situations where the response to NO is sub-optimal. In this
perspective, although less effective than SNAP in physio-
logical conditions, CORM-3 could be a good candidate
when the NO/cGMP/cGMP-dependent protein kinase path-
way is impaired.
Acknowledgments We are grateful to Mrs. Mary Forrest for English
revision.
This work was supported by grants from the University of Florence
and Ente Cassa di Risparmio di Firenze
Dr. Roberto Motterlini has financial interest with Alfama Inc. (Lisbon,
Portugal). The remaining authors have not disclosed any conflict of
Interest.
References
1. Maines MD. The heme oxygenase system: a regulator of second
messenger gases. Annu Rev Pharmacol Toxicol. 1997;37:517–54.
2. Morse D, Sethi J, Choi AM. Carbon monoxide-dependent signal-
ing. Crit Care Med. 2001;30:S12–7.
3. Ndisang JF, Tabien HE, Wang R. Carbon monoxide and hyperten-
sion. J Hypertens. 2004;22:1057–74.
4. Mannaioni PF, Vannacci A, Masini E. Carbon monoxide: the bad
and the good side of the coin, from neuronal death to anti-
inflammatory activity. Inflamm Res. 2006;55:261–73.
5. Lin H, McGrath JJ. Vasodilating effects of carbon monoxide. Drug
Chem Toxicol. 1988;11:371–85.
6. Ignarro LJ. Biological actions and properties of endothelium-
derived nitric oxide formed and released from artery and vein.
Circ Res. 1989;65:1–21.
7. Schmidt HH. NO., CO and OH. Endogenous soluble guanylyl
cyclase-activating factors. FEBS Lett. 1992;307:102–7.
8. Stone JR, Marletta MA. Soluble guanylate cyclase from bovine
lung: activation with nitric oxide and carbon monoxide and spec-
tral characterization of the ferrous and ferric state. Biochemistry.
1994;33:5636–40.
9. Ma X, Sayed N, Beuve A, van den Akker F. NO and CO differ-
entially activate soluble guanylyl cyclase via a heme pivot-bend
mechanism. EMBO J. 2007;26:578–88.
Cardiovasc Drugs Ther (2012) 26:285–292 291
10. Wang R, Wang Z, Wu L. Carbon monoxide-induced vaso-
relaxation and the underlying mechanisms. Br J Pharmacol.
1997;121:927–34.
11. Motterlini R, Clark JE, Foresti R, Sarathchandra P, Mann BE,
Green CJ. Carbon monoxide-releasing molecules: characteriza-
tion of biochemical and vascular activities. Circ Res. 2002;90:
e17–24.
12. Clark JE, Naughton P, Shurey S, Green CJ, Johnson TR,Mann BE, et
al. Cardioprotective actions by a water-soluble carbon monoxide-
releasing molecule. Circ Res. 2003;93:2–8.
13. Foresti R, Hammad J, Clark JE, Johnson TR, Mann BE, Friebe A,
Green CJ, Motterlini R. Vasoactive properties of CORM-3, a novel
water-soluble carbon monoxide-releasing molecule. Br J Pharma-
col. 2004;142:453–60.
14. Rubanyi GM, Polokoff MA. Endothelins: molecular biology, bio-
chemistry, pharmacology, physiology, and pathophysiology. Phar-
macol Rev. 1994;46:325–415.
15. Dostal DE, Murahashi T, Peach MJ. Regulation of cytosolic cal-
cium by angiotensins in vascular smooth muscle. Hypertension.
1990;15:815–22.
16. Tarquini R, Masini E, La Villa G, Barletta G, Novelli M,Mastroianni
R, et al. Increased plasma carbon monoxide in patients with
viral cirrhosis and hyperdynamic circulation. Am J Gastro-
enterol. 2009;104:891–7.
17. Franchi-Micheli S, Failli P, Mazzetti L, Bani D, Ciuffi M, Zilletti
L. Mechanical stretch reveals different components of endothelial-
mediated vascular tone in rat aortic strips. Br J Pharmacol.
2000;131:1355–62.
18. Mazzetti L, Franchi-Micheli S, Nistri S, Quattrone S, Simone R,
Ciuffi M, et al. The ACh-induced contraction in rat aortas is
mediated by the Cys Lt1 receptor via intracellular calcium mobi-
lization in smooth muscle cells. Br J Pharmacol. 2003;138:707–15.
19. Ko FN, Wu CC, Kuo SC, Lee FY, Teng CM. YC-1, a novel
activator of platelet guanylate cyclase. Blood. 1994;84:4226–33.
20. Zhou X, Frohlich ED. Analogy of cardiac and renal complications
in essential hypertension and aged SHR or L-NAME/SHR. Med
Chem. 2007;3:61–5.
21. Sacerdoti D, Escalante B, Abraham NG, McGiff JC, Levere RD,
Schwartzman ML. Treatment with tin prevents the development
of hypertension in spontaneously hypertensive rats. Science.
1989;243:388–90.
22. Wynne BM, Chiao CW, Webb RC. Vascular smooth muscle cell
signaling mechanisms for contraction to angiotensin II and
endothelin-1. J Am Soc Hypertens. 2009;3:84–95.
23. Ruetten H, Zabel U, Linz W, Schmidt HH. Downregulation of
soluble guanylyl cyclase in young and aging spontaneously hyper-
tensive rats. Circ Res. 1999;85:534–41.
24. Di Cesare Mannelli L, Nistri S, Mazzetti L, Bani D, Feil R, Failli P.
Altered nitric oxide calcium responsiveness of aortic smooth mus-
cle cells in spontaneously hypertensive rats depends on low ex-
pression of cyclic guanosine monophosphate-dependent protein
kinase type I. J Hypertens. 2009;27:1258–67.
25. Wu L, Cao K, Lu Y, Wang R. Different mechanisms underlying the
stimulation of K(Ca) channels by nitric oxide and carbon monox-
ide. J Clin Invest. 2002;110:691–700.
26. Rusch NJ, De Lucena RG, Wooldridge TA, England SK, Cowley
Jr AW. A Ca(2+)-dependent K+ current is enhanced in arterial
membranes of hypertensive rats. Hypertension. 1992;19:301–7.
27. England SK, Wooldridge TA, Stekiel WJ, Rusch NJ. Enhanced
single-channel K + current in arterial membranes from genetically
hypertensive rats. Am J Physiol. 1993;264:H1337–45.
28. Jaggar JH, Li A, Parfenova H, Liu J, Umstot ES, Dopico AM, Leffler
CW.Heme is a carbonmonoxide receptor for large-conductance Ca2+-
activated K+ channels. Circ Res. 2005;97:805–12.
29. Telezhkin V, Brazier SP, Mears R, Müller CT, Riccardi D, Kemp
PJ. Cysteine residue 911 in C-terminal tail of human BK(Ca)α
channel subunit is crucial for its activation by carbon monoxide.
Pflugers Arch. 2011;461:665–75.
292 Cardiovasc Drugs Ther (2012) 26:285–292
